Article

Valganciclovir as Add-on to Second Line Therapy in Patients with Recurrent Glioblastoma

2022-01-13

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>Glioblastoma invariably recurs despite aggressive and multimodal first line treatment and no standardized second line therapy exists. We previously reported that treatment with the antiviral drug valganciclovir as an add-on to standard therapy significantly prolonged overall survival in 102 patients with newly diagnosed glioblastoma. Here we present the results...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f702c4bb-01ca-5594-8344-8c8c7fc3ba1c
DOI: 10.21203/rs.3.rs-1246592/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest

Valganciclovir as Add-on to Second Line Therapy in Patients with Recurrent GlioblastomaDOI 10.21203/rs.3.rs-1246592/v1Read

Very Late Recurrence of Glioblastoma after 8 Years of Progression-Free Survival: A Case Report and Review of Tumor DormancySemantic proximity Read

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.Semantic proximity Read

Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastomaSemantic proximity Read

Anlotinib plus Temozolomide for Recurrent Glioma: A Single-Center, Retrospective Study of 30 casesSemantic proximity Read

Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma.Semantic proximity Read

Targeted and Systemic therapies for recurrent adult ependymomas: real- world outcomes from a single institution and concise literature reviewSemantic proximity Read

Different Recurrence and Growth Pattern of Gliomatous Foci after Mesenchymal Stem Cell Harbouring the Herpes Simplex Thymidine Kinase Gene Transplantation in Multifocal Glioblastoma Multiform: A Clinical Case ReportSemantic proximity Read

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Semantic proximity Read

A phase I trial investigating the clinical safety and anti-tumor efficacy of a new generation of oncolytic adenovirus, Ad-TD-nsIL12, in Recurrent GlioblastomaSemantic proximity Read